1. Signaling Pathways
  2. Neuronal Signaling
  3. Glucosylceramide Synthase (GCS)
  4. Glucosylceramide Synthase (GCS) Inhibitor

Glucosylceramide Synthase (GCS) Inhibitor

Glucosylceramide Synthase (GCS) Inhibitors (11):

Cat. No. Product Name Effect Purity
  • HY-17020A
    Miglustat hydrochloride
    Inhibitor ≥98.0%
    Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat hydrochloride can be used for the research of type I gaucher disease.
  • HY-17020
    Miglustat
    Inhibitor ≥98.0%
    Miglustat (N-Butyldeoxynojirimycin) is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease.
  • HY-116392B
    DL-threo-PDMP hydrochloride
    Inhibitor
    DL-threo-PDMP hydrochloride is the hydrochloride form of DL-threo-PDMP that is a competitive glucosylceramide synthase (GCS) inhibitor. DL-threo-PDMP resensitizes refractory testicular germ cell tumors and epithelial ovarian cancer orthoxenografts to cisplatin in mice.
  • HY-116392D
    PDMP hydrochloride
    Inhibitor ≥99.0%
    PDMP hydrochloride is a glucosylceramide synthase (GCS) inhibitor. PDMP hydrochloride induces apoptosis in K562/A02 cells. PDMP hydrochloride can be used in cancer (such as leukemia) research.
  • HY-114615
    AMP-Deoxynojirimycin
    Inhibitor
    AMP-Deoxynojirimycin (AMP-DNM) is a potent ceramide glucosyltransferase and GCase 2 inhibitor. AMP-Deoxynojirimycin also is a GlcCer biosynthesis inhibitor.
  • HY-155715
    G43
    Inhibitor
    G43 is a potent, selective glucosyltransferase inhibitor, with the Kd of 3.7μM and 46.9 nM for GtfB and GtfC, respectively. G43 has antibacterial to S. mutans in vitro and in vivo, and can be used for dental caries study.
  • HY-155716
    G43-C3-TEG
    Inhibitor
    G43-C3-TEG is a glycosyl-transferase inhibitor. G43-C3-TEG reduces the biofilm formation by decreasing the production of EPS (extracellular polysaccharides).
  • HY-116392E
    D-threo-PDMP
    Inhibitor
    D-threo-PDMP is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth.
  • HY-148786
    Nizubaglustat
    Inhibitor
    Nizubaglustat is an inhibitor of Ceramide Glucosyltransferase or Glucosylceramide Synthase (GCS). Nizubaglustat also inhibits GBA2, involving in neuropathological lysosomal storage disorders.
  • HY-116392A
    (−)-L-threo-PDMP hydrochloride
    Inhibitor
    (−)-L-threo-PDMP hydrochloride is the hydrochloride form of (−)-L-threo-PDMP. L-threo-PDMP is a glucosylceramide synthase (GCS) inhibitor. L-threo-PDMP stimulates the proliferation of cultured aortic smooth muscle cells, and that increases the level of LacCer in B16 melanoma cells.
  • HY-163131
    Glucosylceramide synthase-IN-4
    Inhibitor
    Glucosylceramide synthase-IN-4 (compound 12) is a potent glucosylceramide synthase (GCS) inhibitor, with an IC50 of 6.8 nM. Glucosylceramide synthase-IN-4 shows excellent PK properties and stability in human hepatocytes. Glucosylceramide synthase-IN-4 has good CNS penetration and acceptable PXR selectivity.